Skip to content

Our Cancer Immunotherapy
Development Pipeline

Our precision cancer therapies generate systemic therapeutic effects and have demonstrated favorable tolerability profiles to date. See the progress of our CAN-2409 and CAN-3110 platforms in development.

Microscopic view capturing a t cell actively attacking an infected cell, featuring a transparent background, ideal for use in medical and scientific projects focused on immunology and biology

Our Cancer Immunotherapy
Development Pipeline

Our precision cancer therapies generate systemic therapeutic effects and have demonstrated favorable tolerability profiles to date. See the scientific progress of our aglatimagene besadenovec and linoserpaturev platforms in development.

bg-hero-floating-cells

Pipeline

We are currently evaluating our viral immunotherapies in a variety of solid tumors, including prostate, lung and brain cancer. For more information on our clinical studies, please visit our science page to learn more about our viral immunotherapy approach.

Program

Indication

Preclinical

Phase I

Phase II

Phase III

BLA Readiness

Adenovirus Platform

Aglatimagene Pancreatic Cancer*

Borderline Resectable Pancreatic Adenocarcinoma, Fast Track Designation (FDA), Orphan Drug Designation (FDA)

Phase II

Aglatimagene Lung Cancer

NSCLC + PD-1/PD-(L)1,
Fast Track Designation (FDA)

Phase III

Aglatimagene Prostate Cancer

Localized, Intermediate/High Risk,
Fast Track Designation (FDA),
Special Protocol Assessment (FDA), Regenerative Medicine Advanced Therapy Designation (FDA)

BLA Readiness

HSV Platform

Linoserpaturev Brain Cancer

Recurrent High-Grade Glioma, Fast Track Designation (FDA), Orphan Drug Designation (FDA)

Phase I

enLIGHTEN™ Discovery Platform

Solid Tumors

Preclinical

SPA – special protocol assessment
*Development paused, subject to additional funding

Clinical Trials

Discover active clinical trials and see the data from our completed prostate cancer clinical trial. 

Teenage oncology patient talking with doctor. Oncologist treating teen girl with cancer and provide emotional support, helping her with anxiety and depression.

The Science

Learn why our viral immunotherapies offer the potential to improve overall survival and quality of life. 

Modified drugs blocks DNA synthesis in dividing tumor cells, leading to tumor cell death. Adenovirus capsid proteins attract immune cells to the tumor microenvironment. Activated immune cells then attack distant metastases.

Join us in bringing life-saving cancer therapies to patients everywhere. Explore Candel Therapeutics' corporate profile

The products described on this website are investigational products. They have not been reviewed or approved by the U.S. Food and Drug Administration (FDA), and safety and effectiveness has not been established.